Flazoparib and temozolomide after standard treatment for glioblastoma
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (flazoparib and temozolomide) given after the standard initial treatment for glioblastoma. The goal is to see if this combination is safe and effective in preventing the cancer from growing back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma (a type of brain cancer).
- You are between 18 and 69 years old.
- You have completed the standard first treatment (radiation and a chemotherapy called temozolomide given together).
- You had surgery that removed at least 80% of the tumor (not just a biopsy).
- You have acceptable kidney, liver, and blood test results.
- You are generally able to care for yourself (Karnofsky score of 60 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.